QuartzBio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
QuartzBio - overview
Location
Frederick, MD, US
Primary Industry
Healthcare IT
About
QuartzBio, based in the US, specializes in Sample and Biomarker Intelligence, empowering clinical-stage biopharma teams with comprehensive data insights through its innovative platform. QuartzBio is focused on enhancing clinical trial data management and biomarker intelligence. The company is headquartered in Frederick, US. It has successfully completed one deal, with the most recent investment occurring on 13 May 2026.
The CEO and founder's details are not currently disclosed. Their latest funding round was led by Eir Partners, with financial terms not disclosed, allowing the company to bolster its product development and automation capabilities. QuartzBio offers a comprehensive suite of solutions specifically designed to provide Sample and Biomarker Intelligence for clinical-stage biopharma teams. The core product, the QuartzBio platform, enables users to conversationally interact with their clinical, sample, and biomarker data ecosystems, delivering real-time insights.
This platform offers a 360° view of clinical trial samples from collection to long-term storage and manages biomarker data through quality control, indexing, and mapping, facilitated by a network of domain-specific AI agents. They serve approximately 25% of the top pharmaceutical companies and 20% of leading biotechnology firms, primarily in North America and Europe. QuartzBio generates revenue through a subscription-based model, providing access to flagship services like Sample Intelligence™ and Biomarker Intelligence™. Clients typically enter into annual agreements, which may include tiered pricing for different levels of access.
Revenue is driven by biopharma companies' demand for improved data management and operational efficiency, emphasizing efficiency and time savings for users, aligning with the growing need for innovative data solutions in the life sciences sector. QuartzBio aims to support its product development and automation capabilities following the recent investment from Eir Partners in May 2026. The company plans to introduce new features to its platform and expand its services into additional markets in North America and Europe by late 2026. The funding will be utilized to enhance product offerings and streamline operations to meet the evolving needs of their clients.
Current Investors
Eir Partners
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT
Website
www.quartz.bio/
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
QuartzBio - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | QuartzBio | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.